A pilot study of prednisone in alzheimer’s disease

Paul S. Aisen, Deborah Marin, Larry Attstiel, Catherine Goodwin, Bella Baruch, Rachel Jacobson, Theresa Ryan, Kenneth L. Davis

Research output: Contribution to journalArticlepeer-review

48 Scopus citations


Prelimininary to a multicenter trial, an open-label pilot study was conducted of prednisone treatment in Alzheimer’s disease. Prednisone was given at an initial dose of 10 mg (part 1) or 20 mg (part 2) and tapered over 7 weeks. There were no serious adverse events attributed to the medication, and there were no significant changes in either mean cognitive or behavioral assessment scores with treatment during either part. Serum levels of the acute phase proteins α-1-antichymotrypsin and C-reactive protein did not change significantly during part 1, but were suppressed by the higher dose given in part 2. Thus, a prednisone regimen with an initial dose of 20 mg is tolerable and results in suppression of the acute phase response in Alzheimer’s disease.

Original languageEnglish
Pages (from-to)201-206
Number of pages6
JournalDementia and Geriatric Cognitive Disorders
Issue number4
StatePublished - 1 Jan 1996


  • Acute phase response
  • Alzheimer’s disease
  • Glucocorticoids
  • Inflammation


Dive into the research topics of 'A pilot study of prednisone in alzheimer’s disease'. Together they form a unique fingerprint.

Cite this